Current Report Filing (8-k)
June 28 2023 - 9:01AM
Edgar (US Regulatory)
0001187953false00011879532023-06-272023-06-27iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):June 27, 2023
Creative Medical Technology Holdings, Inc. |
(Exact name of registrant as specified in its charter) |
Nevada | | 000-53500 | | 87-0622284 |
(State or other jurisdiction Identification Number) | | (Commission File Number) | | (I.R.S. Employer of incorporation) |
211 E Osborn Road, Phoenix, AZ 85012
(Address of principal executive offices)
(480) 399-2822
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common Stock, par value $0.001 per share | CELZ | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On June 27, 2023 Creative Medical Technology Holdings, Inc. (the “Company”), received written notice from the Nasdaq Stock Market notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Stock Market because the closing bid price of the Company’s common stock was greater than $1.00 for 10 consecutive trading days, from June 12, 2023 to June 26, 2023.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Creative Medical Technology Holdings, Inc. | |
| | |
Date: June 28, 2023 | By: | /s/ Timothy Warbington | |
| | Timothy Warbington, Chief Executive Officer | |
Creative Medical Technol... (NASDAQ:CELZ)
Historical Stock Chart
From Apr 2024 to May 2024
Creative Medical Technol... (NASDAQ:CELZ)
Historical Stock Chart
From May 2023 to May 2024
